Paper Details

  1. Home
  2. Paper Details

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.

Author: , AckaertOliver, AghemoAlessio, BeumontMaria, BiermerMichael, BourgeoisStefan, BuggischPeter, ButiMaria, CorbettChris, FeveryBart, GreenbloomSusan, JanczewskaEwa, KalmeijerRonald, LamperticoPietro, LimSeng Gee, MorenoChristophe, Ouwerkerk-MahadevanSivi, SinhaRekha, TamEdward, VijgenLeen, WillemsWouter, ZeuzemStefan

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy and safety of a 6- or 8-week treatment regimen with three direct-acting antiviral agents (AL-335, odalasvir, and simeprevir) in patients with chronic hepatitis C virus (HCV) infection. The study found high sustained virologic response rates (98.9% and 97.8% after 6 and 8 weeks, respectively) with good tolerability, suggesting this regimen may be an effective and safe treatment option for HCV infection.
Paper Details　
Original Abstract of the Article :
The combination of three direct-acting antiviral agents (AL-335, odalasvir, and simeprevir: JNJ-4178 regimen) for 6 or 8 weeks demonstrated good efficacy and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected patients without cirrhosis and has now been evaluated ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hep.30527

データ提供：米国国立医学図書館（NLM）

A Promising Triple Threat: JNJ-4178 for Hepatitis C

This research explores the efficacy and safety of a triple drug regimen, known as JNJ-4178, for treating chronic hepatitis C virus (HCV) infection. It's like a team of skilled warriors, each with their own strengths, working together to combat a formidable enemy. The researchers, like generals leading a campaign, conducted a phase IIb study to evaluate the effectiveness of this regimen in patients with HCV genotypes 1, 2, 4, 5, or 6. They found that the JNJ-4178 regimen, administered for 6 or 8 weeks, achieved high sustained virologic response (SVR) rates, suggesting that it is a potent and well-tolerated treatment option.

A Powerful Combination: Targeting HCV with Precision

This study highlights the remarkable progress made in HCV treatment, with the development of highly effective direct-acting antiviral agents (DAAs) like those included in the JNJ-4178 regimen. It's like crafting a specialized weapon to target the virus, minimizing collateral damage to the body. These DAAs have revolutionized HCV treatment, offering a new hope for patients.

A New Era of HCV Treatment: A Journey Towards Eradication

This research underscores the importance of continued research and development of novel therapies for HCV infection. It's like a caravan venturing into unexplored territory, seeking to conquer this formidable disease. With the development of highly effective regimens like JNJ-4178, we are closer than ever to achieving the ambitious goal of eliminating HCV infection globally.

Dr. Camel's Conclusion

This research highlights the impressive efficacy and safety of the JNJ-4178 regimen in treating chronic HCV infection. It's a significant advance in the fight against this challenging disease, offering hope for a healthier future for patients. This study is a testament to the power of scientific innovation and a reminder of the ongoing journey towards eradicating HCV infection.

Date :
  1. Date Completed 2020-06-15
  2. Date Revised 2020-12-10
Further Info :

Pubmed ID

30693573

DOI: Digital Object Identifier

10.1002/hep.30527

Related Literature

Article Analysis
・Effects of simeprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.